Opexa Wins Positive Review for Phase IIb Multiple Sclerosis Study
Posted on: Wednesday, 9 July 2008, 06:00 CDT
Opexa Therapeutics has announced that the data safety monitoring board overseeing the on-going Phase IIb clinical study of Tovaxin has recommended that the trial continue unmodified.
This positive recommendation follows a regularly scheduled meeting of the data safety monitoring board (DSMB) in June 2008, and is based upon an evaluation of clinical, magnetic resonance imaging (MRI) and safety data that had been recorded for all patients to date.
The Terms trial is nearing completion and the DSMB has two additional scheduled meetings in July and August of 2008. Tovaxin is being evaluated in a multi-center, randomized, double blind, placebo controlled study in 150 patients suffering from relapse remitting multiple sclerosis (RRMS) or clinically isolated syndrome.
The primary endpoint being evaluated in this trial is the cumulative number of contrast (gadolinium) enhancing brain lesions (CEL) using MRI, an important and objective measure of MS disease activity. Secondary endpoints include annualized relapse rate and additional MRI measurements. Opexa expects to announce top line results in September 2008.
Source: Datamonitor
Related Articles
- BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
- Pervasis Therapeutics to Present Safety and Efficacy Data From Phase 1 and 2 Clinical Trials of Vascugel(R) at the 35th Annual VEITHsymposium(TM)
- BioMS Medical's Phase III U.S. Multiple Sclerosis Trial Receives Positive Safety Review From Data Safety Monitoring Board
- MicroIslet Provides Safety and Efficacy Data Update
- Apthera Reports Positive Safety and Efficacy Data of Breast Cancer Drug
- BioMS Medical's Phase III U.S. Multiple Sclerosis Trial Receives Positive Safety Review From Data Safety Monitoring Board
- Thallion Announces Positive Safety and Efficacy Data From ECO-4601 Phase I/II Trial
- U.S. Track Delegation Tours Akron Courses: Committee Seeks Site for 2008 Olympic Marathon Trials
- AVI BioPharma Reports Favorable Safety and Pharmacokinetic Data From Its Clinical Trial Targeting Hepatitis C Virus; NEUGENE Antisense Compound Was Well-Tolerated and Exhibited Favorable Pharmacokinetic Parameters
- Genmab A/S and Medarex Announce Positive Safety and Efficacy Data in Phase I/II Trial With HuMax-Inflam/MDX-018
 |
 |
User Comments (0)
RSS Feeds